$STIM

Chernett Jorey purchased $44K of STIM

Chernett Jorey purchased 14,000 shares of Neuronetics, Inc. (STIM) at $3.16 on 2026-08-14.

Original reporting
SEC EDGAR · Chernett Jorey
Published Aug 17, 2026, 2:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 2:46 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STIM
Bullish
medium confidence
Mentioned
$STIM
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STIMBullishLow
01

Why it matters

The newest information is the disclosed open-market purchase of 14,000 shares at $3.1600 on 2026-08-14, filed on 2026-08-17.

02

Market read

Traders may treat the insider buy as a small sentiment input, but the article lacks any new fundamental catalyst.

03

What to watch

The filing does not state motivations, timing constraints, or whether the insider already held a large position; traders may discount the trade relative to broader fundamentals.

Relevance 4/10Novelty 4/10Timing: filed 2026-08-17, transaction dated 2026-08-14

Background

This is an SEC Form 4 insider transaction for Neuronetics, Inc. (STIM) by 10% owner Chernett Jorey.

Company-level read

Ticker impact

$STIMBullishMedium confidence
Context

Neuronetics Form 4 shows 10% owner Chernett Jorey bought 14,000 shares at $3.1600 on 2026-08-14 for $44,240.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

Form 4 provides a fresh, primary-source transaction, but the article contains no new company-specific operational, financial, or regulatory development beyond the insider trade.

Market effects

No sector-wide signal; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine or planned; without a 10b5-1 plan and with a small dollar amount, the signal may be weak.

Key entities

  • Neuronetics, Inc.

    Company subject of the Form 4 insider transaction (STIM).

  • Chernett Jorey

    10% owner who purchased 14,000 shares open-market at $3.1600.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STIMMedAI 8/10

Neuronetics (STIM) Q2 2026 Earnings Call Transcript

Neuronetics (STIM) reported Q2 2026 revenue of $41.6M, up 9.1% YoY. Greenbrook revenue grew 16.8% YoY, while NeuroStar revenue fell 2.7% YoY. Net loss narrowed to $3.4M. Full-year revenue guidance was set at $160M-$164M, with gross margin guidance raised to 48%-50%. The company expanded NeuroStar acquisition options and integrated AI into operations. Management highlighted growth opportunities in psychedelic-based therapies and strategic collaborations.

Med

Neuronetics, Inc. Q2 2026 Earnings Call Summary

Neuronetics reported Q2 2026 progress on its NeuroStar commercial shift to hybrid capital purchase and lease options, with 17% YoY growth at Greenbrook clinics and a 10% utilization increase in active NeuroStar accounts. Management expects choppier H2 2026 revenue, raised full-year gross margin guidance to 48%-50%, and cut operating expense guidance by $5M.

$STIMMedAI 8/10

Neuronetics Q2 Earnings Call Highlights

Neuronetics (NASDAQ:STIM) reported Q2 Worldwide NeuroStar revenue of $14.7M, down 2.7% YoY, with capital revenue up and treatment-session revenue down. The company expanded NeuroStar purchase and leasing options, expects no further material inventory reduction in H2, and plans to report NeuroStar as a single revenue line. Gross margin rose to 61.1% and 2026 guidance was narrowed to $160M-$164M.

$STIMHighAI 8/10

Why is Neuronetics stock surging today?

Neuronetics shares rose about 24% in pre-open after the company reported Q2 2026 results that beat Wall Street on revenue and EPS. Revenue was $41.6M (+9.1% YoY). Net loss narrowed to $3.4M, or -$0.05/share, versus -$10.1M and -$0.15/share a year earlier. Greenbrook revenue grew to $26.9M (+16.8%).

$STIMMed

Neuronetics, Inc. (STIM): Results of Operations and Financial Condition

Neuronetics, Inc. (STIM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Neuronetics Reports Second Quarter 2026 Financial and Operating Results MALVERN, PA., August 11, 2026 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combines its NeuroStar ® TMS technology with direc